Panasonic Announces Signing of Professional Women’s Tennis Player Naomi Osaka as Brand Ambassador
24.6.2021 10:48:00 EEST | Business Wire | Press release
Panasonic Corporation has signed a brand ambassador agreement with professional women's tennis player Naomi Osaka. The period of agreement is two years starting from April 22, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005399/en/
Panasonic’s Brand Ambassador Naomi Osaka (Graphic: Business Wire)
Panasonic sought the agreement with Ms. Osaka after observing that her values and perspectives on society deeply resonate with its own management philosophy, primarily with regard to the following three points:
First, Ms. Osaka takes social issues seriously, looking beyond tennis to share her views on what a better society would look like in her own words. The founder of Panasonic, Konosuke Matsushita, held the notion that a stable state of happiness comes only when both mental stability and material prosperity are secured. Based on this idea, the company endeavors to create an ideal society where all of us can enjoy lives that are both mentally fulfilling and affluent in the material sense.
Second, Ms. Osaka’s intense and powerful playing is a source of energy and courage for people all over the world. Panasonic has passed down the founder’s view that the mission of an enterprise is to achieve a prosperous society and to make people happy, and continues to work toward fulfilling a strong aspiration not only to provide products needed by society, but also to make customers who use them feel happy and uplifted.
And third, Ms. Osaka continues to grow and evolve as her magnificent track record being one of the world’s top athletes is the result of her tireless efforts to refine each and every move in the course of her daily training and matches. Panasonic also continues to grow and evolve in a range of fields, aiming to elevate its expertise for the benefit of customers and society and achieve constant evolution.
At this time, Panasonic and Ms. Osaka have concluded a brand ambassador agreement to join hands in an endeavor to create an ideal society for each and every person, positioning “A Champion. For Progress.” as our shared commitment.
Ms. Osaka has shown she has the courage to take action in the face of adversity. Panasonic will provide her with heartfelt support.
Reference:
- Panasonic’s management philosophy
https://www.panasonic.com/global/corporate/management/philosophy.html#section_02
- Why Panasonic Appointed Naomi Osaka
https://channel.panasonic.com/contents/33222/
- "A CHAMPION. FOR PROGRESS." - Naomi Osaka, a brand ambassador of Panasonic
https://channel.panasonic.com/contents/33217/
https://channel.panasonic.com/contents/33219/ (Short version)
Naomi Osaka
Profile:
Date of birth: October 16, 1997
Place of birth: Osaka City, Osaka
Height: 180 cm
Naomi Osaka was born to a Japanese mother and a Haitian-American father, who moved her to New York in the United States when she was three years old. She is now based in Florida.
Major achievements:
- 2013: Started her professional career in tennis
- July 2014: Qualified for the first time for the Women’s Tennis Association (WTA) Tour Championships in Stanford
- January 2016: Advanced to the third round at the Australian Open, her Grand Slam debut
- 2016: Also advanced to the third round at the French Open (Roland-Garros) and the US Open Tennis Championships, where she recorded a serve speed of 201.1 km/h
- September 2016: Toray Pan Pacific Open Tennis Tournament runner-up
- October 2016: Named “Newcomer of the Year” at the 2016 WTA Awards, becoming the first Japanese player to win the award
- March 2018: BNP Paribas Open champion
- August 2018: US Open Tennis Championships champion
- January 2019: Australian Open champion
- September 2019: China Open tennis champion
- September 2019: Toray Pan Pacific Open Tennis Tournament champion
- August 2020: US Open Tennis Championships champion
- February 2021: Australian Open champion
Current WTA Ranking: 2nd
Qualified to play at the Olympic Games Tokyo 2020 (Women’s tennis, singles)
About Panasonic
Panasonic Corporation is a global leader developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, and B2B sectors. The company, which celebrated its 100th anniversary in 2018, operates 522 subsidiaries and 69 associated companies worldwide and reported consolidated net sales of 6,698.8 billion yen for the year ended March 31, 2021. Committed to pursuing new value through collaborative innovation, the company uses its technologies to create a better life and a better world for customers. Learn more about Panasonic: https://www.panasonic.com/global
Source: https://news.panasonic.com/global/press/data/2021/06/en210624-3/en210624-3.html
Related Links
- Panasonic’s management philosophy
https://www.panasonic.com/global/corporate/management/philosophy.html#section_02
- Why Panasonic Appointed Naomi Osaka
https://channel.panasonic.com/contents/33222/
- "A CHAMPION. FOR PROGRESS." - Naomi Osaka, a brand ambassador of Panasonic
https://channel.panasonic.com/contents/33217/
https://channel.panasonic.com/contents/33219/ (Short version)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005399/en/
Contact information
Panasonic Corporation
Corporate PR Department
Click here to go to Media Contact form
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom